STOCK TITAN

Femasys Inc. (FEMY) CFO invests $50,000 and is granted stock warrants

(Neutral)
(Positive)
Form Type
4

Rhea-AI Filing Summary

Femasys Inc. Chief Financial Officer Dov Elefant reported new equity transactions. On August 7, 2026, he purchased 15,625 shares of common stock at $3.20 per share for an aggregate $50,000 under a Securities Purchase Agreement. He also received two direct grants of common stock purchase warrants, each for 15,625 shares at an exercise price of $2.95 per share. One warrant is exercisable from August 10, 2026 until August 10, 2029, subject to Nasdaq Capital Market limitations. The milestone warrant becomes exercisable only after a future Milestone Date tied to achieving $1,500,000 in U.S. quarterly revenue and specified volume-weighted average price conditions.

Positive

  • None.

Negative

  • None.
Insider Elefant Dov
Role Chief Financial Officer
Bought 15,625 shs ($50K)
Type Security Shares Price Value
Grant/Award Common Stock Purchase Warrant F2, F4, F3 15,625 -- --
Grant/Award Common Stock Purchase Warrant (Milestone) F2, F4, F5, F3 15,625 -- --
Purchase Common Stock F1 15,625 $3.20 $50K
Holdings After Transaction: Common Stock Purchase Warrant — 15,625 shares (Direct); Common Stock Purchase Warrant (Milestone) — 15,625 shares (Direct); Common Stock — 15,625 shares (Direct)
Footnotes (5)
  1. F1. The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto.
  2. F2. Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.
  3. F3. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.
  4. F4. The reported securities were purchased by the reporting person for an aggregate amount of $50,000.
  5. F5. The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.
Common shares purchased 15,625 shares Common Stock purchased on August 7, 2026
Purchase price per share $3.20 per share Price for common stock under Securities Purchase Agreement
Aggregate purchase amount $50,000 Aggregate amount paid for reported securities
Warrant exercise price $2.95 per share Exercise price of common stock purchase warrants
Standard warrant shares 15,625 shares Underlying common shares for standard warrant grant
Milestone warrant shares 15,625 shares Underlying common shares for milestone warrant grant
Revenue milestone $1,500,000 U.S. revenue for any fiscal quarter required for Milestone Date
Common Stock Purchase Warrant financial
"Holder may, at its option, exercise the Common Warrant"
A common stock purchase warrant is a tradable certificate that gives its holder the right to buy a company’s common shares at a fixed price for a set period. Think of it as a coupon that lets you buy stock later at today’s agreed price; it can amplify gains if the share price rises but also can increase the total number of shares outstanding, which may reduce existing owners’ percentage of the company. Investors watch warrants because they offer leveraged upside and can affect future share value and ownership.
Milestone Date financial
"The Common Warrant (Milestone) is exercisable only from and after the Milestone Date"
volume-weighted average price financial
"the volume-weighted average price of the Common Stock has satisfied certain price conditions"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.
Nasdaq Capital Market financial
"subject to certain limitations, in accordance with rules of the Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Femasys (FEMY) CFO Dov Elefant buy in this Form 4 filing?

Femasys CFO Dov Elefant purchased 15,625 shares of common stock at $3.20 per share. The total purchase price was $50,000, made under a Securities Purchase Agreement dated August 7, 2026 with Femasys Inc. and other purchasers.

What warrants were granted to the Femasys (FEMY) CFO in this transaction?

He was granted two common stock purchase warrants, each for 15,625 shares at an exercise price of $2.95 per share. One is a standard warrant, and the other is a milestone-based warrant with additional performance and price conditions.

When can the Femasys (FEMY) standard warrant granted to the CFO be exercised?

The standard common stock purchase warrant for 15,625 shares is exercisable, at the holder’s option, from August 10, 2026 until August 10, 2029, subject to limitations described as being in accordance with Nasdaq Capital Market rules.

What conditions govern the milestone warrant in the Femasys (FEMY) CFO Form 4?

The milestone warrant becomes exercisable only after a Milestone Date when Femasys reports $1,500,000 or more in U.S. revenue for any fiscal quarter and the stock’s volume-weighted average price satisfies warrant-specified conditions, with its expiration tied to registration and milestone notice timing.

Are there limitations on exercising the Femasys (FEMY) warrants granted to the CFO?

Yes. A footnote states the holder’s ability to exercise the warrant for common stock is subject to certain limitations under Nasdaq Capital Market rules. These limitations apply to the subject warrant’s exercise for shares of common stock.

What total dollar amount did the Femasys (FEMY) CFO invest in these reported securities?

The reported securities were purchased for an aggregate amount of $50,000. This aggregate figure applies to the securities described, including the common stock purchased at $3.20 per share as referenced in the Securities Purchase Agreement footnote.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Elefant Dov

(Last)(First)(Middle)
C/O FEMASYS INC.
3950 JOHNS CREEK COURT, SUITE 100

(Street)
SUWANEE GEORGIA 30024

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
FEMASYS INC [ FEMY ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/07/2026P15,625A$3.2(1)15,625D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Common Stock Purchase Warrant$2.95(2)08/07/2026A15,62508/10/202608/10/2029Common stock, par value $0.001 per share15,625(3)(4)15,625D
Common Stock Purchase Warrant (Milestone)$2.95(2)08/07/2026A15,62508/10/2027(5) (5)Common stock, par value $0.001 per share15,625(3)(4)15,625D
Explanation of Responses:
1. The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto.
2. Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.
3. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.
4. The reported securities were purchased by the reporting person for an aggregate amount of $50,000.
5. The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.
/s/ Kathy Lee-Sepsick, Attorney-in-fact08/11/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)